This math rests on two constants being true:

1. The generic for Gleevec (imatinib mesylate) costing $9k

2. Gleevec costing $100k retail

Neither of which have been true since Gleevec went generic (sensationalist reporting). Brandname imatinib mesylate costs $9-12k depending on insurance. You can get a rebate card that lowers that to around $200. Generic it's around $100-150 for a month's supply.

I really dislike pharmaceutical practices, but there are systems already in place that will allow actual "consumers" (patients, not hospitals and other orgs) to pay a reasonable price for the medication they need.

This really is no different than the Shkreli debacle.